Open in interactive viewer → charts, metric popovers & call review

Delcath's Record Quarter Is Priced Like a Niche Device—and Guided Like a Holiday Calendar

Q3 revenue jumped 71%, the full-year guide went up, and the stock still sits 14% below its August peak. The debate is whether Q4 conservatism hides a bigger demand curve.
DCTH · Earnings Call · 2026-11-09

The beat was real; the guide is the tell

Delcath's third quarter was a genuine outlier. “Delcath's record third quarter of $35.1 million in revenue, up 71% in the third quarter in 2025” — Gerard Michel, Chief Executive Officer · 2026-11-09 The HEPZATO KIT did $32.7 million, up 72%, and the company crossed its 1,000th commercial U.S. treatment. The analyst on the call called it “several million more than I think folks were expecting” — Marie Thibault, Analyst · 2026-11-09. Yet the stock, at a $518 million market cap, is still about 14% below its August peak and trades at 4.6x revenue, down 32% year over year. That is the setup: operating momentum has outrun the multiple.

The full-year guide went up to $115 million to $117 million, but the Q4 line implies $25.8 million to $27.8 million—roughly a quarter lower sequentially at the midpoint. Chase Knickerbocker of Craig-Hallum pressed exactly that point. Gerard Michel's answer was calendar arithmetic: “we essentially lose close to two weeks due to the holidays” — Gerard Michel, Chief Executive Officer · 2026-11-09. He also said the company assumes Q4 new patient starts return to last year's 0.3 to 0.35 range rather than the 0.6 just reported.

That is the tension. In February, Sandra Pennell told investors to expect “a bit of a maybe flat to modest growth from Q2 to Q3” — Sandra Pennell, Chief Financial Officer · 2026-02-26. Q3 revenue instead rose about 17% sequentially. The company has already under-forecast seasonality once this year; the Q4 haircut may be prudence, but investors should treat it as a management assumption, not a demand signal.

The yardstick changed

Delcath now asks investors to track 0.6 new patient starts per site per month. That is not the same metric it used in 2025, when Gerard said “We are slightly over 2 treatments per center, which is great.” — Gerard J. Michel, Chief Executive Officer · 2025-08-06 The shift matters: treatments per center captures repeat doses and capacity; new starts captures the top of the funnel. Both can be true—patients get multiple treatments—but the new metric puts the spotlight on referral and activation, the two things management controls least well.

There were 33 active treatment centers at quarter-end, with the University of Nebraska and AdventHealth added. AdventHealth alone has more than 50 hospitals and roughly 4 million patients a year, which is why the center count matters less than the referral funnel behind it. Management expects at least 36 centers by year-end; two more have patients scheduled, and another three or so could slip in. Gerard was candid about the forecast risk:

I've been woefully inaccurate in my projections for new centers, but I've also overperformed on the new starts per center, so we've done okay.

Gerard Michel, Chief Executive Officer · 2026-11-09

That is the right way to read the model: center adds are lumpy, but utilization at mature sites is the real lever. The 0.6 starts rate was described as broad-based, with MD Anderson and Mass General adding capacity and backup teams. Combination therapy with systemic treatment is now more norm than exception, which keeps patients on therapy longer.

The pipeline is the fresh signal

The Clinical Development story changed. The colorectal trial interim is now expected in Q2 or Q3 2027; in May, the company was pointing to the end of 2027: “we'll be able to share interim results publicly by the end of next year, '27” — Vojislav Vukovic, Chief Medical Officer · 2026-05-07. Gerard's current language: “Q2, Q3 is probably when we'll provide an update on the interim results.” — Gerard Michel, Chief Executive Officer · 2026-11-09 That is a meaningful pull-forward, not a guidance tweak.

Breast remains the slow child—the first patient was dosed in July at the European Institute of Oncology in Milan, but management explicitly declined to guide on interim timing. The bigger new theme is oxaliplatin. Delcath plans to finish preclinical work on an oxaliplatin-based PHP program by mid-2027, with a subsequent IND. Physicians already know oxaliplatin as a backbone in colorectal and GI cancer; the pitch is regional delivery without adding cumulative neuropathy. Add a planned IND submission for cholangiocarcinoma in early 2027, and the pipeline has moved from 'two trials' to a platform story. The keyword history mirrors it: oxaliplatin was the biggest riser in the latest company keyword set, while colorectal trial had been a decliner a year ago—now the trial is the one speeding up.

Cash buys the patience to be wrong on timing

The balance sheet is no longer the constraint. Sandra: “We ended the quarter with $104.3 million in cash and investments and no debt.” — Sandra Pennell, Chief Financial Officer · 2026-11-09 Cash generated from operations was $8.2 million. Gross margin was 89%, and the July quarter already showed 89.8% gross margin. Revenue in that July quarter was $29 million, up 21% year over year; Q3 added another $6 million. R&D rose to $11 million from $8 million, and SG&A to $13.1 million from $10.3 million, but the operating leverage is still visible: net income was $7 million and adjusted EBITDA $11.5 million.

The bear case is not demand; it is timing. Q4 guidance may prove conservative, breast enrollment is slower than hoped, and center activations remain lumpy. The 340B pricing final rules, Gerard said, should be “net neutral to a net positive for us in terms of ASP without any impact on volume” — Gerard Michel, Chief Executive Officer · 2026-11-09. At 4.6x revenue with positive operating cash flow, Delcath is priced like a niche device company while the numbers are starting to look like a platform. If the Q4 guide is just holiday math, the next re-rating may not wait for 2027.